Werkgroep Cardiologische centra Nederland

SURMOUNT (Follow-up)

The study will assess the effect of tirzepatide at the maximum tolerated dose (10 mg or 15 mg QW) compared with placebo in people living with obesity
Medicine
Tirzepatide
Population
ASCVD
Phase
III
Starting year
2022

Director of Study

drs. M.J. Asselman (Cardioloog)
Tiel, Rivierenland